Video presentation of real-world research on the impact of upfront chemo choice on second-line immunotherapy in bladder cancer. CONTEXT: Lead author Benjamin Miron presents findings of a real-world study into Continue Reading
Implications of the upcoming changes to French ATU (Autorisation Temporaire d’Utilisation) programme CONTEXT: From July of 2021manufacturers will be required to make all early access authorisation requests to the HAS Continue Reading
High-fidelity simulation model developed to assess impact of new technologies in critical care setting. CONTEXT: Not our usual RWR based story, but another example of the increasing use of “in-silico” Continue Reading
Holmusk and Otsuka team up to develop real-world evidence based behavioural health platform. CONTEXT: Commercial announcement that Holmusk and Otsuka are partnering to develop one of the largest real-world evidence Continue Reading
ALK present results of huge real-world evidence study on allergy immunotherapy (AIT) in asthma CONTEXT: ALK presented the results on the long term effects of allergy immunotherapy (AIT) on asthma Continue Reading
Real-world research papers presented at the American Diabetes Association annual meeting. CONTEXT: The Annual meeting of the American Diabetes Association held virtually this year attracted more than 11,500 participants. Just Continue Reading
The role of family health history in predicting midlife chronic disease outcomes. CONTEXT: This longitudinal real-world research study published in the American Journal of Preventive Medicine looked at the relevance Continue Reading
Are decentralised trials here to stay? Who knows…. CONTEXT: This is an opinion piece from Veradigm® asking whether decentralised trials will live on beyond the pandemic and as they have Continue Reading
French researchers first exposure to decentralised trials CONTEXT: Discussion article on one French company’s first experience with the concept of decentralised clinical trials and how they went about solving the Continue Reading
First data from EMPRISE Real-World Evidence study in type 2 diabetes reveals risk reduction for patient on Empagliflozin compared to DPP-4 inhibitors CONTEXT: Interim analysis of the EMPRISE real-world evidence Continue Reading
